Prevalence of uropathogens in urine and their resistance patterns: data analysis from a single centre

Czech version

Authors: Jan Hrbáček ¹; Pavel Čermák ²; Vítězslav Hanáček ¹; Vanda Adamcová ¹; Lucie Bartáková ¹; Roman Zachoval ¹
Authors‘ workplace: Urologická klinika 3. LF UK a Thomayerovy nemocnice, Praha ¹; Oddělení klinické mikrobiologie, Thomayerova nemocnice, Praha ²
Published in: Ces Urol 2019; 23(4): 316-324
Category: Original Articles

Overview

Introduction: Antibiotic resistance is a major issues in contemporary health care, including in the speciality of urology. Multi‑drug resistant bacteria are now commonplace not just in the hospital environment, but also in the community. The objective of thiswork was to investigate the prevalence of uropathogens and their resistance patterns in our department.

Methods: Data on prevalence and antibiotic resistance of uropathogenic bacteria were extracted from the electronic database for the Department of Urology for the year 2017.

Results: A total of 2036 individual uropathogens were detected between 1st January and 31st December 2017. E. coli was the most common(n = 726, 35.7 %), followed by Enterococcus sp. (n = 495, 24.3 %) and Klebsiella sp. (n = 206, 10.1 %).

A half of E. Coli isolates were ciprofloxacin‑resistant and 36 % were co‑trimoxazol‑resistant. Klebsiella sp. were markedly resistant to ciprofloxacin (58.4 %), over a quarter were also resistant to amoxicillin‑clavulanate, cefalotin, cefuroxime, cefotaxime, ceftazidime, co‑trimoxazole, ofloxacin, piperacillin‑tazobactam and tetracycline.

A total of 155 multi‑drug resistant pathogens were detected. Most of them belonged among extended‑spectrum beta‑lactamase (ESBL, n = 108) positive Enterobacteriaceae.

No gram‑negative rod except Pseudomonas aeruginosa proved resistant to meropenem or imipenem. There was no vancomycin‑resistant isolates of S. aureus and Enterococcus sp. detected.

Conclusion: Our data on prevalence and resistance of uropathogenic microorganisms are comparable to those from the literature in our geographic area. They confirm high rates of resistance to many commonly used antimicrobials.

Keywords:

antibiotics – resistance – Urinary tract infections – uropathogens – ESB

Sources

1. Zowawi HM, Harris PN, Roberts MJ, et al. The emerging threat of multidrug‑resistant Gram‑negative bacteria in urology. Nat Rev Urol. 2015; 12(10): 570–584.

2. Bonkat G, Pickard R, Bartoletti R, et al. EAU Guidelines on Urological Infections. European Association of Urology. 2017.

3. Le Fanu J. The Rise and Fall of Modern Medicine. Hachette, Londýn 2011; 13–20. ISBN 978‑0‑349‑12375‑2.

4. Bonkat G, Müller G, Braissant O, et al. Increasing prevalence of ciprofloxacin resistance in extended‑spectrum‑β‑lactamase‑producing Escherichia coli urinary isolates. World J Urol. 2013; 31(6): 1427–1432.

5. Fajfr M, Louda M, Paterová P, et al. The susceptibility to fosfomycin of Gram‑negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study. BMC Urol. 2017; 26; 17(1): 33.

6. Magyar A, Köves B, Nagy K, et al. Spectrum and antibiotic resistance of uropathogens between 2004 and 2015 in a tertiary care hospital in Hungary. J Med Microbiol. 2017; 66(6): 788–797.

7. Toner L, Papa N, Aliyu SH, et al. Extended‑spectrum beta‑lactamase‑producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. World J Urol. 2016; 34(7): 1031–1037.

8. Sbiti M, Lahmadi K, Louzi L. Epidemiological profile of uropathogenic enterobacteria producing ex‑ tended spectrum beta‑lactamases]. Pan Afr Med J. 2017; 13: 28–29.

9. Girometti N, Lewis RE, Giannella M, et al. Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy. Medicine (Baltimore) 2014; 93(17): 298–309.

10. Cho YH, Jung SI, Chung HS, et al. Antimicrobial susceptibilities of extended‑spectrum beta‑lactamase‑producing Escherichia coli and Klebsiella pneumoniae in health care ‑associated urinary tract infection: focus on susceptibility to fosfomycin. Int Urol Nephrol. 2015; 47(7): 1059–1066.

11. Concia E, Azzini AM. Aetiology and antibiotic resistance issues regarding urological procedures. J Chemother. 2014; 26Suppl 1: S14–23.

12. Vallée M, Bruyère F, Roblot F, Brureau L. Temocillin and urinary tract infections. Prog Urol. 2017; 27(12): 609–617.

13. Wagenlehner FM, Alidjanov JF. Efficacy, pharmacokinetic and pharmacodynamics profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections. Expert Opin Drug MetabToxicol. 2016; 12(8): 959–966.

14. Stapleton PJ, Lundon DJ, McWade R, et al. Antibiotic resistance patterns of Escherichia coli urinary isolates and comparison with antibiotic consumption data over 10 years, 2005–2014. Ir J Med Sci. 2017; 186(3): 733–741.

15. Jiménez ‑Alcaide E, Medina ‑Polo J, García ‑González L, et al. Healthcare‑associated urinary tract infections in patients with a urinary catheter: Risk factors, microbiological characteristics and patterns of antibiotic resistance]. Arch Esp Urol. 2015; 68(6): 541–550.

16. Černohorská L, Sláviková P. Pseudomonas aeruginosa, její rezistence k vybraným antibiotikům a tvorba biofilmu u kmenů izolovaných od pacientůs infekcí močových cest. Epidemiol Mikrobiol Imunol. 2009; 58(4): 154–157.

17. Toner L, Papa N, Aliyu SH, et al. Vancomycin resistant enterococci in urine cultures: Antibiotic susceptibility trends over a decade at a tertiary hospital in the United Kingdom. Investig Clin Urol. 2016; 57(2): 129–134.

18. Lara ‑Isla A, Medina ‑Polo J, Alonso‑Isa M, et al. Urinary Infections in Patients with Catheters in the Upper Urinary Tract: Microbiological Study. Urol Int. 2017; 98(4): 442–448.

19. Cai T, Mazzoli S, Lanzafame P et al. Asymptomatic bacteriuria in Clinical Urological Practice: Preo‑ perative Control of Bacteriuria and Management of Recurrent UTI. Pathogens 2016; 5: 4. doi: 10.3390/ pathogens5010004.

20. Routh JC, Alt AL, Ashley RA, Kramer SA, Boyce TG. Increasing prevalence and associated risk factors for methicillin resistant Staphylococcus aureus bacteriuria. J Urol. 2009; 181(4): 1694–1698.

21. Heidler S, Asboth F, Mert C, Madersbacher S. Methicillin ‑resistant Staphylococcus aureus (MRSA) in an Austrian urological department: 10 years experience covering 95161 patients. World J Urol. 2013; 31(3): 559–563.

22. Gohel K, Jojera A, Soni S, et al. Bacteriological profile and drug resistance patterns of blood culture isolates in a tertiary care nephrourology teaching institute. Biomed Res Int. 2014; 2014: 153747.

23. Dopis členů panelu doporučených postupů EAU pro léčbu uroinfekcí, dostupné z: http://www.cus.cz/wp‑content/uploads/2019/06/Communication‑letter‑fluoroquinolones.pdf.